Biovica: Adding capital and market reach - Redeye

Biovica records SEK 2.3m in total net sales (22% above Q4 last year), and clinical sales increased by 120%. The outlook includes improved post-Q4 sales, the approaching support from Tempus AI later this calendar year, and a sound momentum in pharma-related sales. The company is executing a fully guaranteed rights issue of SEK 80m, sufficient to break even by Q3 2026/27 based on Biovica’s sales targets.

Länk till analysen i sin helhet: https://www.redeye.se/research/1115976/biovica-adding-capital-and-market-reach?utm_source=finwire&utm_medium=RSS